Clinical guideline recommendations for antipsychotic long-acting injections

British Journal of Psychiatry

Volumn 195, Issue SUPPL. 52, 2009, Pages

  Kane, John M ^a   Garcia Ribera, Carlos ^b  

^a ZUCKER HILLSIDE HOSPITAL   (United States)

^b HOSPITAL DEL MAR   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

NEUROLEPTIC AGENT; RISPERIDONE;

HUMAN; INJECTION; LONG TERM CARE; PATIENT COMPLIANCE; PRACTICE GUIDELINE; PSYCHOSIS; RELAPSE; REVIEW; RISK ASSESSMENT; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SCHIZOPHRENIFORM DISORDER; TREATMENT REFUSAL; TREATMENT RESPONSE; ATTITUDE TO HEALTH; DELAYED RELEASE FORMULATION;

ANTIPSYCHOTIC AGENTS; DELAYED-ACTION PREPARATIONS; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HUMANS; INJECTIONS; MEDICATION ADHERENCE; PRACTICE GUIDELINES AS TOPIC; PSYCHOTIC DISORDERS;

EID: 71249096481     PISSN: 00071250     EISSN: 14721465     Source Type: Journal    
DOI: 10.1192/bjp.195.52.s63     Document Type: Review

References (27)

1. Kane JM, Aguglia E, Altamura AC, Ayuso-Gutierrez JL, Brunello N, Flelschhacker WW, et al. Guidelines for depot antipsychotic treatment in schizophrenia. Eur Neuropsychopharmacol 1998; 8: 55-66. (Pubitemid 28012861)
2. Kane JM, Quitkin F, Rifkin A, Ramos-Lorenzi JR, Nayak DV. Fluphenazine versus placebo in patients with remitted acute first episode schizophrenia. Arch Gen Psychiatry 1982; 39: 70-73 (Pubitemid 12163378)
3. Crow TJ, MacMillan JF, Johnson AL, Johnstone EC. A randomised controlled trial of prophylactic neuroleptic treatment. Br J Psychiatry 1986; 148: 120-127 (Pubitemid 16158512)
4. Robinson DG, Woerner MG, Delman HM, Kane JM. Pharmacological treatments for first-episode schizophrenia. Schizophr Bull 2005; 31: 705-722
5. Robinson DG, Woerner MG, Alvir JMJ, Geisler S, Koreen A, Sheitman B, et al. Predictors of treatment response from a first episode of schizophrenia or schizoaffective disorder. Am J Psychiatry 1999; 156: 544-549 (Pubitemid 29162974)
6. Harding CM, Zubin J, Strauss JS. Chronicity in schizophrenia: revisited. Br J Psychiatry 1992; 161 (suppl 18): 27-37.
7. Harrow M, Jobe TH. Factors involved in outcome and recovery in schizophrenia patients not on antipsychotic medications: a 15 year multifollow-up study. J Nerv Ment Dis 2007; 195: 406-414 (Pubitemid 46763242)
8. Kane JM, woerner M, Weinhold P, Wegner J, Kinon B. A prospective study of tardive dyskinesia development: preliminary results. J Clin Psychopharmacol 1982; 2: 345-349
9. American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, North American Association for the Study of Obesity. Consensus Development Conference on Antipsychotic Drugs and Obesity and Diabetes. J Clin Psychiatry 2004; 65: 267-273
10. Lehman AF, Steinwachs DM, Survey Co-Investigators of the PORT Project. Patterns of usual care for schizophrenia. Initial results from the Schizophrenia Patient Outcomes Research Team (PORT) Client Survey. Schizophr Bull 1998; 24: 11-20.
11. National Institute for Health and Clinical Excellence. Schizophrenia: Full National Clinical Guideline on Core Interventions in Primary and Secondary Care. Gaskell/British Psychological Society, 2003.
12. American Psychiatric Association Work Group on Schizophrenia. Practice guideline for the treatment of patients with schizophrenia, second edition. Am J Psychiatry 2004; 161 (2 suppl): 1-56.
13. Canadian Psychiatric Association. Clinical practice guidelines: treatment of schizophrenia. Can J Psychiatry 2005; 50 (suppl 1): 7S-56S.
14. Moore TA, Buchanan RW, Buckley PF, Chiles JA, Conley RR, Crismon ML, et al. The Texas Medication Algorithm Project antipsychotic algorithm for schizophrenia: 2006 update. J Clin Psychiatry 2007; 68: 1751-1762
15. Miller AL, Hall CS, Buchanan RW, Buckley PF, Chiles JA, Conley RR, et al. The Texas Medication Algorithm Project antipsychotic algorithm for schizophrenia: 2003 update. J Clin Psychiatry 2004; 65: 500-508
16. Argo TR, Crismon ML, Miller AL, Moore TA, Bendele SD, Suehs B. Texas Medication Algorithm Project Procedural Manual. Schizophrenia Treatment Algorithm. Texas Department of State Health Services, 2008.
17. Fenton WS, Blyler CR, Heinssen RK. Determinants of medication compliance in schizophrenia: empirical and clinical findings. Schizophr Bull 1997; 23: 637-651
18. Lacro JP, Dunn LB, Dolder CR, Leckband SG, Jeste DV. Prevalence of and risk factors for medication nonadherence in patients with schizophrenia: a comprehensive review of recent literature. J Clin Psychiatry 2002; 63: 892-907.
19. Velligan DI, Lam F, Ereshefsky L, Miller AL. Psychopharmacology: perspectives on medication adherence and atypical antipsychotic medications. Psychiatr Serv 2003; 54: 665-667 (Pubitemid 36752956)
20. Velligan DI, Wang M, Diamond P, Glahn DC, Castillo D, Bendle S, et al. Relationships among subjective and objective measures of adherence to oral antipsychotic medications. Psychiatr Serv 2007; 58: 1187-1192 (Pubitemid 47507958)
21. Kane JM, Rifkin A, Quitkin F, Nayak D, Ramos-Lorenzi J, Klein DF, et al. Low dose fluphenazine decanoate in maintenance treatment of schizophrenia. Psychiatry Res 1979; 1: 341-348 (Pubitemid 10123393)
22. Kane JM, Rifkin A, Woerner M, Reardon G, Sarantakos S, Schiebel D, et al. Low-dose neuroleptic treatment of outpatient schizophrenics: I. Preliminary results for relapse rates. Arch Gen Psychiatry 1983; 40: 893-896
23. Schooler NR, Keith SJ, Severe JB, Matthews SM, Bellack AS, Glick ID, et al. Relapse and rehospitalization during maintenance treatment of schizophrenia. Arch Gen Psychiatry 1997; 54: 453-463
24. Waddell L, Taylor M. Attitudes of patients and mental health staff to antipsychotic long-acting injections: systematic review. Br J Psychiatry 2009; 195 (suppl 52): S43-50.
25. Gray R, Spilling R, Burgess D, Newey T. Long-acting injections in clinical practice: medication management and patient choice. Br J Psychiatry 2009; 195 (suppl 52): s51-6.
26. Emsley R, Medori R, Koen L, Oosthuizen PP, Niehaus D, Rabinowitz J. Long-acting injectable risperidone in the treatment of subjects with recent-onset psychosis. J Clin Psychopharm 2008; 28: 210-213
27. Weiden PJ, Schooler NR, Weedon JC, Elmouchtari A, Sunakawa A, Goldfinger SM. Long-acting injectable risperidone vs. continuing on oral atypical antipsychotic for first-episode schizophrenia patients: initial adherence outcomes. J Clin Psychiatry in press.